Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases.
Suguru HiroseChiaki EnamiNatsumi KawamatsuYoshimi ItoTsubasa OnodaYutaro SugiyamaHirosumi SuzukiMiho NagafuchiTakafumi IkedaYusuke NiisatoTakeshi YamadaYoshiyuki YamamotoToshikazu MoriwakiHideo SuzukiPublished in: International cancer conference journal (2021)
The effect of anti-epidermal growth factor receptor (EGFR) antibody-containing chemotherapy on appendiceal signet-ring cell carcinoma (SRCC) remains unknown. Herein, we report three patients, diagnosed as having synchronous metastases, who underwent this treatment for unresectable appendiceal SRCC with RAS wild type. Cases 1, 2, and 3 received FOLFOX with panitumumab, FOLFOX with cetuximab, and FOLFIRI with cetuximab, respectively, and their progression-free survival were 6.2, 7.2, and 18.7 months, respectively. The subsequent anti-vascular endothelial growth factor antibody-containing therapy was ineffective, and their overall survival was 8.2, 11.4, and 22.9 months, respectively. The anti-EGFR antibody-containing chemotherapy showed moderate efficacy for appendiceal SRCC. Further studies including molecular analysis should be needed.
Keyphrases
- wild type
- epidermal growth factor receptor
- tyrosine kinase
- low grade
- advanced non small cell lung cancer
- vascular endothelial growth factor
- free survival
- locally advanced
- small cell lung cancer
- newly diagnosed
- ejection fraction
- rectal cancer
- prognostic factors
- mesenchymal stem cells
- high intensity
- bone marrow
- radiation therapy
- smoking cessation
- cell therapy
- drug induced